Skip to main content

Advertisement

Log in

The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Proton pump inhibitors (PPIs) are among the most misused drugs both at the community and hospital level. Recently, possible risks have been underscored, suggesting the importance of limiting PPI use to proven indications. Objective To survey the appropriateness of PPI use in a University hospital in Italy. Setting Azienda Ospedaliera Universitaria Policlinico ‘P. Giaccone’, in Palermo, Italy. Method A one day-observational study, reviewing patients’ medical records to identify treatments with PPIs and the indications for their use. After discharge, a subgroup of the cohort was followed up to assess the continuation of therapy at home. Appropriateness was evaluated according to the indications stated in the official product information sheet and supported by the AIFA notes. Main outcome measure Prevalence and appropriateness of PPI use in the hospital and after discharge. Results In the index day 62.9 % of 343 evaluable patients received a PPI. In only 29.1 % of these, the treatment could be considered appropriate. The most frequent reasons for inappropriate treatment were stress ulcer prophylaxis in low risk patients and unwarranted gastro-protection in drug treated patients. 30.9 % of patients received PPIs for uncertain indications: of these, 25.7 % were “critical” patients admitted in non-ICU wards. Furthermore, as much as 88.2 % of anticancer drug treated patients received PPIs as gastroprotective agents. At discharge 48.6 % of patients received a prescription to continue PPI therapy at home and 75.9 % of the 83 followed up patients were found to be still taking these drugs after on average 3 months from discharge. Conclusion This study confirms a high proportion of inappropriate PPI therapy into the hospital that translates in a prolonged unnecessary administration in the community setting. Further studies are needed to assess the cost-effectiveness of PPI therapy in subgroups of patients at moderate risk for gastric complications to optimize current guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Morini S, Zullo A, Oliveti D, Chirlatti A, Marmo R, Chiuri DA, et al. A very high rate of inappropriate use of gastroprotection for nonsteroidal anti-infiammatory drug therapy in primary care: a cross-sectional study. J Clin Gastroenterol. 2011;45:780–4.

    Article  CAS  PubMed  Google Scholar 

  2. Cahir C, Fahey T, Tilson L, Teljeur C, Bennet K. Proton pump inhibitors: potential cost reductions by applying prescribing guidelines. BMC Health Serv Res. 2012;12:408. doi:10.1186/1472-6963-12-408.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Gingold AR, Narasimhan G, Augello S, Clain DJ. The prevalence of proton pump inhibitor use in hospitalized patients. Pract Gastroenterol. 2006;30(5):24–34.

    Google Scholar 

  4. Craig DGN, Thimappa R, Anand V, Sebastian S. Inappropriate utilization of intravenous proton pump inhibitors in hospital practice. A prospective study of the extent of the problem and predictive factors. Q J Med. 2010;103:327–35.

    Article  CAS  Google Scholar 

  5. Haroon M, Yasin F, Gardezi SKM, Adeeb F, Walker F. Inappropriate use of proton pump inhibitors among medical inpatients: a questionnaire-based observational study. J R Soc Med Short Rep. 2013;4:36. doi:10.1177/2042533313497183.

    Google Scholar 

  6. Eid SM, Boueiz A, Paranji S, Mativo C, Landis R, Abougergi MS. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med. 2010;49:2561–8.

    Article  PubMed  Google Scholar 

  7. Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Ther Adv Gastroenterol. 2012;5:219–32.

    Article  Google Scholar 

  8. Agenzia Italiana del Farmaco. Note AIFA 2009 Una guida per l’uso appropriato dei farmaci. Bollettino Informazione Farmaci. 2009;16(5–6):193–7.

    Google Scholar 

  9. Agenzia Italiana del Farmaco. Note AIFA 2009 Una guida per l’uso appropriato dei farmaci. Bollettino Informazione Farmaci. 2009;16(5–6):220–2.

    Google Scholar 

  10. Parente F, Cucino C, Gallus S, Bargiggia S, Greco S, Pastore L. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther. 2003;17:1503–6.

    Article  CAS  PubMed  Google Scholar 

  11. Chia CT, Lim WP, Vu CK. Inappropriate use of proton pump inhibitors in a local setting. Singap Med J. 2014;55(7):363–6.

    Article  Google Scholar 

  12. Gupta R, Garg P, Kottoor R, Munoz JC, Jamal MM, Lambiase LR, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J. 2010;103(3):207–11.

    Article  PubMed  Google Scholar 

  13. Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol. 2006;101:2200–5.

    Article  PubMed  Google Scholar 

  14. Nasser SC, Nassif JG, Dimassi HI. Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients. World J Gastroenterol. 2010;16:982–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Sartori S, Trevisani L, Nielsen I, Tassinari D, Panzini I, Abbasciano V. Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury. J Clin Oncol. 2000;18(3):463–7.

    CAS  PubMed  Google Scholar 

  16. Grant K, Al-Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci. 2006;28:189–93.

    Article  CAS  PubMed  Google Scholar 

  17. Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen M. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol. 2010;66:1265–71.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Ntaios G, Chatzinikolaou A, Kaiafa G, Savopoulos C, Hatzitolios A, Karamitsos D. Evaluation of use of proton pump inhibitors in Greece. Eur J Intern Med. 2009;20:171–3.

    Article  PubMed  Google Scholar 

  19. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301:2120–8.

    Article  CAS  PubMed  Google Scholar 

  20. Tleyjeh IM, Abdulhak AAB, Riaz M, Alasmari FA, Garbati MA, AlGhamdi M, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection: a contemporary systematic rewiew and meta-analysis. PLoS One. 2012;7:e50836. doi:10.1371/journal.pone.0050836.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139:1115–27.

    Article  CAS  PubMed  Google Scholar 

  22. Wedemeyer R-S, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37:201–11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Meli M, Malta R, Aprea L, Pasquale A, La Seta C, Di Rosa S, et al. Proton pump inhibitor use in a university teaching hospital. Ital J Med. 2012;6:202–9.

    Article  Google Scholar 

  24. Biasi V, Cassani T, Costa E, Scroccaro G Precisazioni sulle classificazioni e i parametri utilizzati nelle elaborazioni. In: Societa` Italiana di Farmacia Ospedaliera e dei Servizi Farmaceutici delle Aziende Sanitarie. Report SIFO-IMS sulle prescrizioni ospedaliere 2008-9. 2009; Verona: SIFO; p. 7–8.

  25. IMS Institute for Heathcare Informatics. Medicine use and shifting costs of healthcare a review of the use of medicines in the United States in 2013. Report 2014 IMS Health Incorporated. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS.

  26. Gruppo di lavoro OsMed. L’uso dei farmaci in Italia. Rapporto nazionale anno 2013. 2014; Roma: Il Pensiero Scientifico.

  27. Deshpande A, Pasupuleti V, Thota P, Pant C, Mapara S, Hassan S, et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol. 2013;28(2):235–42.

    Article  CAS  PubMed  Google Scholar 

  28. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on stress ulcer prophylaxis. Am J Health Syst Pharm. 1999;56:347–79.

    Google Scholar 

  29. Madsen KR, Lorentzen K, Clausen N, Oberg E, Kirkegaard PR, Maymann-Holler N, et al. Guideline for stress ulcer prophylaxis in the intensive care unit. Dan Med J. 2014;61(3):C4811.

    PubMed  Google Scholar 

  30. Krag M, Perner A, Wetterslev J, Møller MH. Stress ulcer prophylaxis in the intensive care unit: is it indicated? A topical systematic review. Acta Anaesthesiol Scand. 2013;57(7):835–47.

    Article  CAS  PubMed  Google Scholar 

  31. Qadeer MA, Richter JE, Brotman DJ. Hospital-acquired gastrointestinal bleeding outside the critical care unit: risk factors, role of acid suppression, and endoscopy findings. J Hosp Med. 2006;1(1):13–20.

    Article  PubMed  Google Scholar 

  32. Herzig SJ, Vaughn BP, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for nosocomial gastrointestinal tract bleeding. Arch Intern Med. 2011;171(11):991–7.

    Article  PubMed Central  PubMed  Google Scholar 

  33. Yachimski PS, Farrell EA, Hunt DP, Reid AE. Proton pump inhibitors for prophylaxis of nosocomial upper gastrointestinal tract bleeding: effect of standardized guidelines on prescribing practice. Arch Intern Med. 2010;170(9):779–83. doi:10.1001/archinternmed.2010.51.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Chu MP, Ghosh S, Chambers CR, Basappa N, Butts CA, et al. Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. Clin Lung Cancer. 2012;16(1):33–9.

    Article  Google Scholar 

  35. Jianu CS, Lange OJ, Viset T, Qvigstad G, Martinsen TC, Fougner R, et al. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol. 2012;47:64–7.

    Article  CAS  PubMed  Google Scholar 

  36. North of England Dyspepsia Guideline Development Group. Dyspepsia: managing dyspepsia in adults in primary care. London: NICE Clinical Guidelines, No. 17. 2004.

  37. Larsen MD, Schou M, Kristiansen AS, Hallas J. The influence of hospital drug formulary policies on the prescribing patterns of proton pump inhibitors in primary care. Eur J Clin Pharmacol. 2014;70:859–65.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank the physicians of the Policlinico “P. Giaccone” of Palermo Doctors: Alessandra Adamo, Salvo Asciutto, Vincenza Alonge, Mario Belvedere, Sergio Calamia, Giuseppe Cannizzaro, Maria Cappello, Egle Corrado, Bianca Maria Cudia, Francesco D’Arpa, Domenico Di Raimondo, Luisa Falletta, Angelo Ferrante, Fabio Fulfaro, Girolamo Geraci, Vincenzo Geraci, Fabio Giacalone, Lydia Giannitrapani, Antonella Giugno, Maria Pia Imbergamo, Egle Incalcaterra, Nicola Lo Biundo, Francesco Lombardo, Filippo Longo, Carla Maione, Pasquale Mansueto, Antonietta Matina, Gaetano Morreale, Ida Muratori, Mario Napoli, Giuseppe Pistone, Giuseppe Profita, Simona Raso, Giovanni Ruvolo, Francesco Vaccaro, Giorgia Virzì, Giovanni Zabbia, Carmela Zarino for their support in reviewing and evaluating the clinical documentation of patients.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Maria Meli.

Ethics declarations

Funding

No funding was received for this study.

Conflicts of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Meli, M., Raffa, M.P., Malta, R. et al. The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients. Int J Clin Pharm 37, 1152–1161 (2015). https://doi.org/10.1007/s11096-015-0178-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-015-0178-0

Keywords

Navigation